Terlipressin acetate 是一种高度选择性的加压素 V1 受体激动剂，对氧和葡萄糖剥夺/再氧合 (OGD/R) 诱导的肠上皮细胞损伤 (IEC-6) 具有抗炎和抗氧化作用，可用于肝肾综合征和耐去甲肾上腺素的败血性休克的研究。

Terlipressin, a highly selective vasopressin V1 receptor agonist, on oxygen and glucose deprivation/re-oxygenation (OGD/R)-induced damage in intestinal epithelial cells (IEC-6).Terlipressin acetate exerts anti-inflammatory and anti-oxidative effects. Terlipressin acetate has the potential for hepatorenal syndrome and norepinephrine-resistant septic shock research.

Incubation with 25 nM terlipressin significantly improved cell viability, proliferation and apoptosis. Furthermore, terlipressin inhibited the secretion of TNF-α and 15-F2t-isoprostane from IEC-6 cells following OGD/R[1].

Using a mouse nonlethal hepatic IR model, we found terlipressin administration significantly ameliorated IR-induced liver apoptosis, necrosis and inflammation[2].

1884420-36-3

C56H82N16O19S2

1347.49

Terlipressin diacetate anhydrous;Terlipressin acetate anhydrous;醋酸特利加压素

DMSO:95mg/mL (70.50mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years